Anti-Infectives Restore ORKAMBI(®) Rescue of F508del-CFTR Function in Human Bronchial Epithelial Cells Infected with Clinical Strains of P. aeruginosa

Chronic infection and inflammation are the primary causes of declining lung function in Cystic Fibrosis (CF) patients. ORKAMBI(®) (Lumacaftor-Ivacaftor) is an approved combination therapy for Cystic Fibrosis (CF) patients bearing the most common mutation, F508del, in the cystic fibrosis conductance...

Descripción completa

Detalles Bibliográficos
Autores principales: Laselva, Onofrio, Stone, Tracy A., Bear, Christine E., Deber, Charles M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072183/
https://www.ncbi.nlm.nih.gov/pubmed/32092967
http://dx.doi.org/10.3390/biom10020334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072183/
https://www.ncbi.nlm.nih.gov/pubmed/32092967
http://dx.doi.org/10.3390/biom10020334

Ejemplares similares